NEW YORK, NY-Reshma Kewalramani, the Mumbai-born CEO of Vertex Pharmaceuticals, has been named one of the 100 Most Powerful ...

Vertex, Inc. (NASDAQ: VERX) reported solid top-line growth for the second quarter of 2025, driven by rising demand for ...

Kolkata, Aug 7 (PTI) India must focus on building scalable, inclusive, and monetisable AI applications tailored for the next ...

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $41.83, a high estimate of $50.00, and a low estimate of $30.00. This current ...

Following these transactions, Kewalramani directly owns 115,968 shares of Vertex Pharmaceuticals. Based on InvestingPro analysis, the stock currently trades below its Fair Value, with analysts setting ...

Nimblemind.ai – a healthcare startup in Chicago dedicated to offering a faster and safer way to structure, label, and manage ...

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall ...

The RMR Group (Nasdaq: RMR) today announced on behalf of its managed joint venture that it has facilitated a $1.0 billion ...

ANZ Banking Group is to pilot a generative AI-powered upgrade of its Economic Pulse insights platform to help institutional ...

Vertex reported quarterly earnings of 15 cents per share which beat the analyst consensus estimate of 14 cents per share. The ...

Highlights,Vertex, Inc. reached a new twelve-month low amid broader market dynamics.,The firm posted growth in compared to ...

We recently published 10 Stocks Taking the Worst Hit. Vertex Inc. (NASDAQ:VERX) is one of the worst-performing stocks on ...